search
Back to results

Safety and Efficacy of MCG for Diagnosing Coronary Heart Disease

Primary Purpose

Myocardial Ischemia

Status
Completed
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
Magnetocardiograph
Sponsored by
Mayo Clinic
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Myocardial Ischemia

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Subjects with chest pain syndrome or angina equivalent

Sites / Locations

  • Mayo Clinic

Outcomes

Primary Outcome Measures

Primary endpoint will be final clinical diagnosis of ischemia by the primary treating physician. This decision will be based upon evaluation of symptoms, clinical presentation, 12-lead ECG, cardiac enzymes (Troponin I or CKMB).

Secondary Outcome Measures

1. Correlation of MCG with anatomic patency and TIMI flow on coronary angiography
2. Correlation of MCG with functional and laboratory tests

Full Information

First Posted
September 12, 2005
Last Updated
February 14, 2011
Sponsor
Mayo Clinic
Collaborators
CardioMag Imaging
search

1. Study Identification

Unique Protocol Identification Number
NCT00170027
Brief Title
Safety and Efficacy of MCG for Diagnosing Coronary Heart Disease
Official Title
Safety and Efficacy of the CMI Magnetocardiograph Model 2409 for Diagnosing Coronary Heart Disease
Study Type
Interventional

2. Study Status

Record Verification Date
February 2011
Overall Recruitment Status
Completed
Study Start Date
July 2003 (undefined)
Primary Completion Date
July 2007 (Actual)
Study Completion Date
July 2007 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Mayo Clinic
Collaborators
CardioMag Imaging

4. Oversight

5. Study Description

Brief Summary
A magnetocardiograph (MCG) is a medical device capable of recording the magnetic fields that arise from the electrical activity of the heart. It was developed for the general purpose as a noninvasive, non-contact diagnostic tool of obstructive coronary artery disease (CAD), and especially of cardiac ischemia. The overall objective of the present study is to demonstrate the efficacy of this MCG device in the diagnosis of lack of oxygen to an area of the heart (as in an Heart attack) in patients presenting with chest pain.
Detailed Description
The CMI-2409 magnetocardiograph (MCG) is an FDA-approved medical device capable of noninvasive recording of magnetic fields arising from the electrical activity of the heart. This system was developed by CMI for the general purpose of noninvasive, non-contact diagnostics of obstructive coronary artery disease (CAD), and especially of cardiac ischemia. The overall objective of the present study is to demonstrate the efficacy of this MCG device and of the associated MCG method for the detection and diagnosis of ischemia in chest pain patients. The primary objective is to demonstrate that the diagnostic accuracy of the MCG device and method is equivalent to or better than that of a standard 12-lead ECG for detecting the presence of ischemia in patients presenting with chest pain of unknown etiology. In this study the rest MCG data will be analyzed and compared to the results of a rest ECG.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Myocardial Ischemia

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Phase 3
Interventional Study Model
Single Group Assignment
Masking
Double
Allocation
Non-Randomized
Enrollment
250 (Actual)

8. Arms, Groups, and Interventions

Intervention Type
Device
Intervention Name(s)
Magnetocardiograph
Primary Outcome Measure Information:
Title
Primary endpoint will be final clinical diagnosis of ischemia by the primary treating physician. This decision will be based upon evaluation of symptoms, clinical presentation, 12-lead ECG, cardiac enzymes (Troponin I or CKMB).
Secondary Outcome Measure Information:
Title
1. Correlation of MCG with anatomic patency and TIMI flow on coronary angiography
Title
2. Correlation of MCG with functional and laboratory tests

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Subjects with chest pain syndrome or angina equivalent
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Peter A. Smars, M.D. EM
Organizational Affiliation
Mayo Clinic
Official's Role
Principal Investigator
Facility Information:
Facility Name
Mayo Clinic
City
Rochester
State/Province
Minnesota
ZIP/Postal Code
55905
Country
United States

12. IPD Sharing Statement

Links:
URL
http://www.cardiomag.com/
Description
Related Info

Learn more about this trial

Safety and Efficacy of MCG for Diagnosing Coronary Heart Disease

We'll reach out to this number within 24 hrs